Skip to content

Effects of probiotics supplementation on body mass index, blood sugar control, and lipid levels in individuals with type 2 diabetes mellitus

Effects of specific symbiotic supplements on anthropometric measurements, glycaemic control, and lipid profiles among individuals with type 2 diabetes mellitus in two teaching hospitals in Baghdad/Iraq, a double-blind randomized placebo-controlled trial

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ISRCTN
Registry ID
ISRCTN34652973
Enrollment
64
Registered
2024-01-05
Start date
2021-09-01
Completion date
Unknown
Last updated
2025-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 2 diabetes mellitus Nutritional, Metabolic, Endocrine

Interventions

To ensure allocation concealment and blinding, the placebo and probiotic supplements were identically packaged and the main researcher and participants were blinded to the capsule content throughout t
therefore, we selected 12 weeks to observe the effect of the intervention on the variables. The placebo was prepared locally with the help of a pharmacist by adding approximately 200 mg of starch to

Sponsors

Arab Board of Health Specializations in IRAQ
Lead Sponsor
Ministry of Health - Baghdad Al-Karkh Health Dirctorate
Collaborator

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Individuals with T2D according to the criteria of the American Diabetes Association (ADA) for at least 10 months prior to study initiation 2. Individuals aged 30–75 years 3. Individuals with an HbA1c level =6.5% 4. Individuals able to provide informed consent

Exclusion criteria

Exclusion criteria: 1. Individuals who were current smokers 2. Individuals with immunocompromised conditions 3. Individuals with diabetes controlled by insulin 4. Individuals who were pregnant or breastfeeding 5. Individuals with inflammatory bowel disease; pancreatitis; chronic kidney, hepatic, or pulmonary diseases; severe anaemia; or cancer 6. Individuals using nutritional supplements, laxatives, or nonsteroidal anti-inflammatory drugs in the past 3 weeks 7. Individuals using antibiotics within the past 3 months prior to study initiation

Design outcomes

Primary

MeasureTime frame
HbA1C is measured by venous blood sample at baseline and 12 weeks

Secondary

MeasureTime frame
Assessed at baseline and 12 weeks: 1. BMI determined by dividing body weight by the square of height (kg/m2) 2. Waist circumference measured using a non-stretchable tape with 0.1-cm accuracy 3. Fasting blood sugar measured using a fasting venous blood sample 4. Lipid profiles measured using a fasting venous blood sample

Countries

Iraq

Contacts

Public ContactSarah Hayder Ali ;Ban Abdul-Ridha Salman Zalzala ;Al-Hashimi

;

sarahhaider1988@gmail.com;banhashimi@gmail.com+964 (0)7902639659;+964 (0)7901365134

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 6, 2026